|
J Biol Chem, Vol. 274, Issue 29, 20165-20170, July 16, 1999
The Inhibition of Capacitative Calcium Entry Due to ATP Depletion
but Not Due to Glucosamine Is Reversed by Staurosporine*
Sudha
Vemuri and
Richard B.
Marchase
From the Department of Cell Biology, The University of Alabama at
Birmingham, Birmingham, Alabama 35294-0005
 |
ABSTRACT |
The capacitative Ca2+ entry
pathway in J774 macrophages is rapidly inhibited by the amino sugar
glucosamine. This pathway is also inhibited by treatments such as
2-deoxy-D-glucose (2dGlc) or glucose deprivation that
inhibit glycolysis and lead to significant decreases in cellular ATP
and other trinucleotides. We sought to determine whether glucosamine's
effect on capacitative Ca2+ entry was also due to ATP
depletion, as has been suggested recently for its link to insulin
resistance. In contrast to brief treatments with 2dGlc, there was no
significant decrease in ATP following exposure to glucosamine. In
addition, the 2dGlc-mediated inhibition of capacitative
Ca2+ influx was reversed by staurosporine, a microbial
alkaloid that inhibits a broad range of protein kinases. Staurosporine
was also able to reverse the inhibition of capacitative
Ca2+ entry seen following other treatments that decreased
cellular ATP levels, including cytochalasin B and iodoacetic acid.
Other inhibitors of protein kinase C, including bisindolylmaleimide, K252a, H-7, and calphostin C, were unable to mimic this effect of
staurosporine. However, the inhibition of capacitative Ca2+
influx in the presence of glucosamine was not reversed by
staurosporine. These data indicate that the inhibitory action on
capacitative Ca2+ entry of glucosamine is distinct
from that caused by ATP depletion.
 |
INTRODUCTION |
The amino sugar glucosamine has been shown to have a variety of
effects on cell and animal physiology. Numerous reports dating from
over 40 years ago (1, 2) document that dietary glucosamine is
selectively toxic to some experimentally induced tumors in rodents. In
addition, Marshall et al. (3) determined that exogenous glucosamine induced insulin resistance in cultured adipocytes in a
manner similar to that caused by hyperglycemia but at a 40-fold lower
concentration than that required for glucose. They also showed that
inhibition of glucose flux through the hexosamine biosynthetic pathway
prevented hyperglycemia-induced insulin resistance from developing.
These results have been extended to show that insulin resistance
develops in animals infused with glucosamine (4, 5) or in cells (6) and
animals (7) that overexpress the rate-limiting enzyme in the hexosamine
biosynthetic pathway, glutamine:fructose-6-phosphate amidotransferase.
Glucosamine treatment has also been shown to elicit the expression of
transforming growth factor (8), transforming growth factor (9),
and leptin (10) mRNA. However, Hresko et al. (11)
recently presented data attributing at least some of these observations
to glucosamine-induced depletion of cellular ATP.
Glucosamine has also received attention in the lay press (12) and in
limited clinical studies (13, 14) as a treatment for osteoarthritis. It
has been suggested that glucosamine's efficacy is due to a stimulation
in the synthesis of glycosaminoglycans and other glycoconjugates (12,
14), although experimental data supporting this suggestion are limited.
Here, we present data that suggest an alternative mechanism to explain
at least some of glucosamine's effects.
In macrophages and other nonexcitable cells, Ca2+ influx
across the plasma membrane is triggered by the depletion of
Ca2+ from intracellular, inositol
1,4,5-trisphosphate-sensitive stores. The formation of inositol
1,4,5-trisphosphate is not a prerequisite for this influx to be
initiated, as release of Ca2+ from these stores by other
means, including an inhibition of the endoplasmic reticulum
Ca2+-ATPase, can cause this influx pathway to be activated
(15). Thus influx has been termed store-operated (16) or capacitative Ca2+ entry (17).
The mechanisms regulating the capacitative Ca2+ entry
pathway are unknown. It is at present uncertain as to whether
information regarding the concentration of Ca2+ sequestered
in the endoplasmic reticulum is communicated via a direct physical
coupling (18-20) or a diffusible second messenger (calcium influx
factor) (21-25). In addition, several protein kinases (18, 26, 27)
have been proposed as playing regulatory and antagonistic roles in the
capacitative Ca2+ entry pathway.
A facilitating role for certain protein phosphorylation events is
suggested by the findings that depletion of ATP in intact cells
inhibits capacitative Ca2+ entry (28-30), and that okadaic
acid, a phosphatase inhibitor, augments it (31, 32). On the other hand,
in whole cell patch clamp experiments ATP is not necessary for the
activation of the current underlying capacitative Ca2+
entry, and in fact the presence of ATP leads to its inhibition (33).
Also, activators of protein kinase C have repeatedly been found to
regulate this process negatively (18, 26, 27). Staurosporine, an
inhibitor of several protein kinases, including protein kinase C (34),
has in several reports been shown to augment capacitative
Ca2+ entry (35-39). This suggests that different protein
kinases may be active at different steps in the regulation of this
pathway and that the balance among antagonistic regulatory reactions
dependent on protein phosphorylation may dictate the time dependence
and/or steady-state level of Ca2+ influx.
Here, these issues were investigated in cells in which ATP had been
depleted with several inhibitors of glycolysis, including 2-deoxyglucose (2dGlc).1
Following ATP depletion capacitative Ca2+ entry is
inhibited, as might be expected if an activating kinase were operating
less than optimally. However, in the presence of staurosporine a
balance in regulation appears to be re-achieved such that capacitative
Ca2+ entry is substantially restored.
In the course of these investigations monosaccharides other than 2dGlc
were also examined for their effects on capacitative Ca2+
entry. Surprisingly, short incubations with glucosamine and mannosamine were found to selectively inhibit this pathway via a mechanism that was
not accompanied by a loss of ATP and could not be reversed by
staurosporine. This inhibition may be significant to the utilization of
glucosamine as a treatment for osteoarthritis (14), since capacitative
Ca2+ entry is critical to the transcriptional regulation of
cytokines in immune cells (40, 41).
 |
EXPERIMENTAL PROCEDURES |
Cell Culture and Media--
J774 cells (American Type Culture
Collection) were cultured at 37 °C in Dulbecco's modified Eagle's
medium supplemented with 10% fetal calf serum (Life Technologies,
Inc.) and 1% penicillin/streptomycin. Hepes-buffered saline solution
(HBS) comprised 125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM KH2PO4,
10 mM NaHCO3, 1 mM
CaCl2, 20 mM Hepes, pH 7.3.
Measurement of Cytoplasmic Free Ca2+
([Ca2+]i) with Fura-2 AM--
J774 cells
were washed in serum-free Dulbecco's modified Eagle's medium and
resuspended in Dulbecco's modified Eagle's medium containing 1 mg/ml
bovine serum albumin and 2.5 mM probenecid. Probenecid was
added to decrease the leakage of Fura-2 (42). After a 30-min incubation
at 37 °C, the cells were centrifuged, washed, and resuspended in
HBS. Fluorescence measurements were performed in a fluorescence
spectrophotometer (Photon Technologies Inc.) with the cells suspended
in a cuvette in a temperature-controlled chamber (37 °C) equipped
with a magnetic stirrer. The fluorescence intensity was measured at 510 nm with excitation wavelengths of 340 and 380 nm.
[Ca2+]i was calculated as described by
Grynkiewicz et al. (43): [Ca2+]i = Kd × [R Rmin]/[Rmax R] × Sf2/Sb2, where Kd is the Fura-2 dissociation constant for
Ca2+ (224 nM), R is the ratio of the
intensities at 340 nm and 380 nm, and Rmin and
Rmax are the R values at 0 and
saturating levels of Ca2+, respectively.
Sf2/Sb2 is the
ratio of the intensities at 380 nm excitation under
Rmin and Rmax conditions.
In presentations in which traces overlap, base-line values ranged
between 70 and 120 nM with no significant differences being
seen among the various conditions.
Assay for Intracellular ATP Levels--
Cellular ATP levels were
determined using an ATP assay kit (Calbiochem) based on firefly
luciferase-catalyzed oxidation of D-luciferin. The emitted
light was quantitated by luminometry. Cells (106/ml) were
incubated in HBS containing the indicated nutrients or inhibitors for 4 min at 37 °C. The cells were then centrifuged and extracted with 1 M HCl04 at 4 °C. The extracts were
neutralized with 5 M K2CO3. A
10-µl aliquot of the extract was added to 400 µl of HBS buffer, and
the reaction was initiated by addition of the luciferase.
 |
RESULTS |
Staurosporine Reverses the 2dGlc-mediated Inhibition of
Capacitative Ca2+ Influx--
The addition of thapsigargin
to Fura-2-loaded J774 cells leads to a sustained elevation of
[Ca2+]i. This irreversible inhibitor of the
endoplasmic reticulum Ca2+-ATPase causes depletion of
intracellular Ca2+ stores and thereby activates the
capacitative influx of Ca2+ (15). The elevated plateau
value of [Ca2+]i is ~100 nM higher
than the starting base line in J774 macrophages under our standard
assay conditions (Fig. 1A),
reflecting the new balance between Ca2+-extruding
mechanisms active at the plasma membrane and the ongoing capacitative
influx of Ca2+.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Reversal of 2dGlc-mediated inhibition of
capacitative Ca2+ influx by staurosporine.
Fura-2-loaded cells were incubated in HBS containing 5 mM
glucose and 5 mM pyruvate. Prior to the addition of
thapsigargin (Tg, 200 nM) incubations were
performed as follows: A, control; B,
staurosporine (40 nM) for 4 min, C,
staurosporine for 4 min and an additional 4 min in 2dGlc (25 mM); D, 2dGlc for 4 min followed by
staurosporine for 4 min; E, 2dGlc for 4 min. Data shown are
representative of eight separate experiments.
|
|
As we reported previously (30), a 4-min pretreatment with 2dGlc
inhibits the capacitative Ca2+ influx pathway in these
cells (Fig. 1E). We speculated that local changes in ATP
levels caused by 2dGlc could lead to a selective decrease in the
activity of a protein kinase that was necessary for a sustained
capacitative Ca2+ entry, thus altering the equilibrium
between antagonistic kinases controlling this response. Staurosporine
is a microbial alkaloid that was initially described as an inhibitor of
protein kinase C but has since been shown to be a broad range inhibitor
of protein kinase activity (34). Staurosporine augments capacitative
Ca2+ influx in rat parotid acinar (36) and mesangial cells
(38) and modulates Ca2+ responses in Jurkat T lymphocytes
(39). Also, in Xenopus oocytes the t1/2
of inhibition of capacitative Ca2+ entry by GTP S was
found to be increased by staurosporine (37). Most recently, a
staurosporine-sensitive kinase was shown to be critical to the
Ca2+-dependent down-regulation of capacitative
Ca2+ entry in human submandibular gland cells (35). The
effect of staurosporine on capacitative Ca2+ influx in J774
macrophages was therefore tested both with and without 2dGlc pretreatment.
We found that a 5-min incubation with staurosporine, either prior to or
after 2dGlc addition, resulted in approximately an 80% reversal of the
inhibition seen in the presence of 2dGlc alone (Fig. 1, C
and D). As can be seen by comparing Fig. 1, A with E, the
initial peak height following the addition of thapsigargin, in addition
to the capacitative plateau, is lower in the presence of 2dGlc. This is
due not only to the inhibition of capacitative Ca2+ influx
by 2dGlc, but to the ability of 2dGlc to partially deplete intracellular, thapsigargin-sensitive Ca2+ stores (30).
Upon the addition of staurosporine, the 2dGlc-mediated inhibition of
capacitative Ca2+ influx is relieved, although the release
of Ca2+ from intracellular stores is not reversed (Fig. 1
and data not shown). Unlike the finding in rat parotid acinar cells
(44), staurosporine did not affect the capacitative Ca2+
entry pathway in untreated J774 cells (Fig. 1B), even at
concentrations of up to 150 nM. This suggests that the
effect of staurosporine is not due to an inhibition of the plasma
membrane Ca2+ATPase or the opening of a different
Ca2+ channel, but rather to a reversal of the inhibition of
capacitative Ca2+ entry seen with 2dGlc.
The inhibition of capacitative Ca2+ influx by 2dGlc can
also be demonstrated by its addition after the pathway has been
activated. In Fig. 2 Fura-2-loaded cells
were treated with thapsigargin, and once a plateau value for
[Ca2+]i was established, 2dGlc was added. Within
~1 min of its addition [Ca2+]i decreased. The
subsequent addition of 40 nM staurosporine caused
[Ca2+]i to return to the initial, higher plateau
value. Following the recovery of Ca2+ influx by
staurosporine, treatment with SKF 96365, an inhibitor of
Ca2+ influx via the capacitative entry pathway (45), caused
[Ca2+]i to return to base line. This, like the
finding that staurosporine itself caused no increase over the normal
capacitative Ca2+ plateau (Fig. 1), supports the premise
that the effect of staurosporine on Ca2+ influx is
attributable to capacitative Ca2+ entry.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Staurosporine reverses 2dGlc-mediated
inhibition of capacitative Ca2+ entry but does not affect
inhibition by SKF96365. Fura-2-loaded J774 cells were suspended in
HBS containing 5 mM glucose and 5 mM pyruvate.
Tg (200 nM) was added as indicated. Once a stable plateau
value of [Ca2+]i was reached, 25 mM
2dGlc, 40 nM staurosporine (stp), and 20 µM SKF 96365 were added as indicated. Data shown are
representative of five separate determinations.
|
|
Effects of Staurosporine on Other Inhibitory Treatments That
Deplete ATP--
In order to determine whether the effect of
staurosporine is limited to reversing only 2dGlc-mediated inhibition of
capacitative Ca2+ entry, we tried alternate ways of
inhibiting glycolysis. The addition of iodoacetic acid also caused a
decrease in Ca2+ influx that was reversed by the subsequent
addition of staurosporine (Fig.
3A). Addition of cytochalasin
B, an inhibitor of glucose transport (46), also caused a decrease in
Ca2+ influx similar to that seen upon the addition of 2dGlc
(Fig. 3B). The subsequent addition of staurosporine restored
the influx to normal. Dihydrocytochalasin B, which has a similar effect
as cytochalasin B on the cytoskeleton but does not interfere with glucose transport (47), had no effect on capacitative Ca2+
influx (data not shown). This is in agreement with our previous results
indicating that glucose deprivation inhibits the influx of
Ca2+ via the capacitative entry pathway (30). Thus, it
appears that staurosporine is able to reverse compromised capacitative
Ca2+ entry that is accompanied by and presumably due to a
decrease in cellular ATP levels.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
A and B, inhibition of
capacitative Ca2+ influx by cytochalasin B and iodoacetic
acid: reversal by staurosporine. Fura-2-loaded cells were suspended in
HBS containing 5 mM glucose and 5 mM pyruvate.
Tg was added as indicated. Cytochalasin B (cytB, 10 µM), iodoacetic acid (IAA, 1 mM),
and stp (40 nM) were added where indicated. C,
reversal of 2dGlc-mediated inhibition of capacitative Ca2+
influx by glucose. Fura-2-loaded cells were suspended in HBS containing
1 mM glucose and 5 mM pyruvate. Thapsigargin
was added as indicated. The addition of 5 mM 2dGlc led to a
decrease in Ca2+ influx. The subsequent addition of 10 mM glucose (Glc) caused the influx to return to
normal. All data shown are representative of at least three
trials.
|
|
An excess of glucose can overcome the 2dGlc-mediated inhibition in
capacitative Ca2+ influx. As shown in Fig. 3C,
an inhibition of capacitative Ca2+ entry can also be
achieved by the addition of 5 mM 2dGlc to cells suspended
in medium containing 1 mM glucose. Upon the addition of
excess glucose (10 mM), the inhibition is reversed. As
expected, the reversal in this case is accompanied by an increase in
cellular ATP levels (data not shown).
Inhibition of Capacitative Ca2+ Entry by Glucosamine
and Mannosamine--
We next sought to determine the effects of a
4-min incubation with monosaccharides other than 2dGlc on the
activation of capacitative Ca2+ influx by thapsigargin. As
shown in Fig. 4, galactose, mannose, N-acetylglucosamine, and 3-O-methylglucose were
without effect. However, glucosamine and mannosamine caused nearly
complete inhibition in the ongoing elevation of Ca2+,
indicating an absence of capacitative Ca2+ influx.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of capacitative Ca2+
entry by glucosamine and mannosamine. Fura-2-loaded J774 cells
were suspended in HBS containing 5 mM glucose and 5 mM pyruvate. Incubation in the presence of various
monosaccharides (25 mM) was performed for 5 min. Tg (200 nM) was then added to deplete intracellular
Ca2+ stores and initiate Ca2+ influx via the
capacitative pathway. A is the control response;
B, C, D, and E are
responses in the presence of galactose, N-acetylglucosamine,
mannose, and 3-O-methylglucose, respectively; F
and G indicate responses in the presence of glucosamine and
mannosamine, respectively. All sugars were tested at least four times
with comparable results.
|
|
The inhibition in capacitative Ca2+ entry by these amino
sugars can also be demonstrated in a Ca2+ add-back
experiment. Fura-2-loaded J774 cells were suspended in a nominally
Ca2+-free buffer. Glucosamine was added 5 min prior to the
addition of thapsigargin. Following release from intracellular stores, Ca2+ was added to the medium so that the entry of
Ca2+ via the capacitative Ca2+ pathway could be
observed in isolation (Fig. 5).
Glucosamine caused little change in the release of intracellular
Ca2+ from stores by thapsigargin. However, the capacitative
entry of Ca2+ was clearly inhibited.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibition of capacitative Ca2+
entry by glucosamine in a Ca2+ add-back protocol.
Glucosamine (25 mM) was added 5 min prior to the addition
of Tg in the nominal absence of extracellular Ca2+. At the
time indicated 1.5 mM extracellular Ca2+ was
added. Trace shown is representative of three replicate
experiments.
|
|
We asked if staurosporine could reverse the inhibition of the
capacitative Ca2+ influx seen in the presence of the amino
sugars. As shown in Fig. 6, staurosporine
was unable to reverse the inhibition in capacitative Ca2+
influx that is brought about by the action of glucosamine or mannosamine.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of staurosporine on capacitative
Ca2+ influx in the presence of amino sugars.
Fura-2-loaded cells were suspended in HBS containing 5 mM
glucose and 5 mM pyruvate. Thapsigargin was added as
indicated. The cells were pretreated in the following manner: 4 min in
25 mM glucosamine (A), 4 min in 25 mM glucosamine followed by 4 min in 40 nM stp
(B), 4 min in 25 mM mannosamine (C),
4 min in mannosamine followed by 4 min in stp (D), and no
addition (E). All conditions were assessed at least three
times with comparable results.
|
|
Intracellular ATP Levels Are Not Altered by Glucosamine or
Staurosporine--
Since glucosamine's link to insulin resistance has
been attributed to ATP depletion (11), we asked if, like 2Glc, short term glucosamine treatments sufficient to inhibit capacitative Ca2+ entry would lead to drops in cellular ATP levels. A
4-min treatment in the presence of the amino sugars did not decrease
ATP levels to an extent that was statistically significant. This is in
contrast to the much more substantial decreases obtained with 2dGlc
(Fig. 7).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
Intracellular ATP measurements. ATP
content was assayed as described under "Experimental Procedures."
The cells were incubated in HBS containing 5 mM glucose and
5 mM pyruvate along with the indicated components. The
concentrations used for the various additives are as follows.
Glucosamine (GlcN) and mannosamine (ManN), 25 mM; stp, 40 nM; 2dGlc, 25 mM;
iodoacetic acid (IAA), 1 mM; cytochalasin B
(cytB), 10 µM. The data obtained under test
conditions were compared with control using paired t tests. Means are
from four determinations. **, p > 0.05; ***,
p < 0.001.
|
|
The effect of staurosporine on cellular ATP levels was also
investigated. Staurosporine had no effect on ATP levels in the presence
or absence of 2dGlc. Thus, staurosporine is not reversing the
2dGlc-mediated inhibition by countering the effect of 2dGlc on
intracellular ATP levels.
Staurosporine's Target Does Not Appear to Be Protein Kinase
C--
Based on previous reports on the involvement of protein kinases
in the capacitative pathway for Ca2+ entry, the most likely
target for staurosporine's action is protein kinase C (35, 37). To
determine whether staurosporine was having its effects via inhibition
of this serine/threonine kinase, the effects of alternate protein
kinase C inhibitors were examined. K252a, bisindolylmaleimide,
calphostin C, and H-7 were all unable to mimic the effect of
staurosporine (Fig. 8). A dose response with staurosporine (Fig. 9) also revealed
that its effect is not likely to be due to protein kinase C inhibition,
since the IC50 for protein kinase C inhibition has been
reported to be ~5 nM (34), whereas a concentration of
~18 nM is half-maximal for the reversal of the inhibition
of capacitative Ca2+ influx in our experiments.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
Effects of other inhibitors of protein kinase
C on capacitative Ca2+ entry. Fura-2-loaded cells were
suspended in HBS containing 5 mM glucose and 5 mM pyruvate. Tg was added as indicated, and after a plateau
value was reached, 25 mM 2dGlc was added. This was followed
by the addition of 1 µM calphostin C (A), 500 nM H-7 (B), 1 µM nM
K252a (C), and 200 nM bisindolemaleimide (D).
All kinase inhibitors were tested at least three times with comparable
results.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 9.
Dose-dependent effect of
staurosporine on capacitative Ca2+ influx. Tg was
added to Fura-2-loaded cells suspended in HBS containing 5 mM glucose and 5 mM pyruvate, and a stable
plateau of [Ca2+]i was achieved. At each of the
staurosporine concentrations used, the new plateau value of
Ca2+ was then measured following the addition of nothing
further or stp alone (A); the latter is depicted as a
percent of the former; 25 mM 2dGlc or 25 mM
2dGlc and then 4 nM staurosporine (B); 25 mM 2dGlc or 40 nM stp and then 2dGlc (C). In
B and C the percent reversal of the
2dGlc-mediated inhibition seen as a result of staurosporine treatment
is depicted. Each determination is the mean of three independent
experiments.
|
|
Other experiments were performed to determine whether activators of
protein kinase C might cause a decrease in capacitative Ca2+ entry similar to that seen with 2dGlc. Phorbol
myristate acetate, an activator of protein kinase C, did not have any
effects on the capacitative influx pathway in these cells in the
presence or absence of 2dGlc. Phorbol myristate acetate has been shown previously to inhibit the Ca2+ response to IgG in these
cells (42). The finding that in our experiments phorbol myristate
acetate was again able to suppress the response to IgG excludes the
possibility that under the conditions/concentrations used the phorbol
ester was ineffective in activating protein kinase C in our cells (data
not shown).
 |
DISCUSSION |
We had shown previously an inhibition of capacitative
Ca2+ influx within 4 min of 2dGlc treatment or glucose
deprivation in J774 macrophages (30). Here, we found that
staurosporine, a microbial alkaloid that inhibits a broad range of
protein kinases, is able to reverse the 2dGlc-mediated inhibition of
the capacitative Ca2+ influx pathway. The decreases in
influx following other means of inhibiting glycolysis were also
reversed by staurosporine. However, the identity of staurosporine's
target remains unclear, as protein kinase C does not appear to be the
object of its action.
We also found that the amino sugars glucosamine and mannosamine
inhibited capacitative Ca2+ influx. The inhibitory action
of these amino sugars appears to be distinct from that of 2dGlc. This
conclusion is based in part on our observation that in the presence of
either of these sugars there was no significant decrease in ATP levels.
In addition, all treatments investigated that led to an inhibition of
the capacitative Ca2+ pathway that was accompanied by a
decrease in cellular ATP were reversed by the addition of
staurosporine. In contrast, the inhibitory effects of glucosamine and
mannosamine were not reversed by this kinase inhibitor.
The mechanism by which staurosporine restores the block in capacitative
Ca2+ entry caused by depletion of ATP is still
undetermined. It is likely that protein kinases play regulatory and
possibly counter-balancing roles in controlling the magnitude of
capacitative Ca2+ influx. It is possible that an activating
kinase is preferentially inhibited when ATP levels fall, allowing an
inhibitory kinase with a lower Km for ATP to
dominate. This could be responsible for the inhibition seen with 2dGlc
and other glycolytic inhibitors. In such a model, staurosporine is
proposed to selectively inhibit the proposed inhibitory kinase so as to
allow the system to re-achieve a balance permissive for capacitative
Ca2+ influx. A related possibility is that a
staurosporine-sensitive inhibitory kinase with a low
Km for ATP is kept in check by phosphorylation. When
ATP falls, it becomes dephosphorylated and in turn phosphorylates and
thereby inhibits an element important for capacitative Ca2+ entry.
In evaluating such models it should be noted that an activating kinase
does not appear to be essential for the initiation of capacitative
Ca2+ entry, at least in patch clamp experiments. When such
experiments are carried out with no ATP in the pipette solution
capacitative Ca2+ entry activates within minutes of whole
cell break-in (33). The relationship between this mechanism of
activation and the necessity for ATP in whole cell experiments observed
both by us (30) and, for instance, Gamberucci et al. (28) is
still unclear. It should also be noted that a decrease in GTP cannot be
experimentally dissociated from a decrease in ATP (33). Thus, the
inhibitory effects observed with 2dGlc could be due to decreases in a
trinucleotide other than ATP.
Previously, staurosporine had been shown in a variety of cell types to
augment capacitative Ca2+ influx (36-39). In several of
these experiments staurosporine's effect targeted a kinase other than
protein kinase C, since other inhibitors of this enzyme were, as seen
here, ineffective. The most parsimonious explanation for the data
presented here is that staurosporine's effect is on a protein kinase
that is capable of inactivating capacitative Ca2+ entry and
that is relatively resistant to the initial decreases in intracellular
ATP brought about by glycolytic inhibitors.
The assertion that glucosamine can affect biological processes via a
mechanism independent of ATP depletion contrasts with arguments
recently put forth by Hresko et al. (11). They reported that
glucosamine treatment of 3T3-L1 adipocytes dramatically decreased cellular ATP and that subsequently this prevented normal levels of
insulin-stimulated protein phosphorylation from occurring. Furthermore,
they suggested that this was the mechanism responsible for the insulin
resistance caused by glucosamine in these cells. They went on to
suggest that many of the other biological effects of glucosamine were
likely to be due to ATP depletion. However, in the data presented here
and in a related study by Bounelis et
al.2 we did not observe
significant decreases in ATP in response to short term glucosamine
treatments. The difference between our findings and those reported by
Hresko et al. (11) would appear to be due to the provision
of alternate fuels from which ATP can be generated. In our experiments
5 mM glucose and 5 mM pyruvate were present
along with glucosamine. In the experiments reported by Hresko et
al. (11) the cells were starved for glucose for several hours
prior to the addition of glucosamine. This no doubt exacerbated ATP
depletion and would appear to be a significant procedural difference
relative to the experiments reported here. Under conditions in which
glucose is present along with glucosamine, the data presented here and
elsewhere2 suggest that a non-ATP-dependent
inhibition of capacitative Ca2+ entry must be considered as
a mechanism by which glucosamine affects cell physiology. In addition,
a recent publication by Kim et al. (5) showed following
glucosamine treatment no inhibition of insulin-stimulated
phosphorylation of the insulin receptor or IRS-1. The authors concluded
that the inhibition caused by glucosamine was at a step distal to these
early phosphorylation events.
In a related study by Bounelis et al.,2 we have
determined that short term glucosamine inhibits capacitative
Ca2+ entry in Jurkat T lymphocytes, RBL-2 cells, and BHK-21
cells. In those experiments, the influx and metabolism of glucosamine was followed utilizing [3H]glucosamine. We observed an
increase in intracellular levels of glucosamine, glucosamine-6-P, and
UDP-GlcNAc. The most likely candidate for mediating the effect of
extracellular glucosamine on capacitative Ca2+ entry is the
initial intracellular metabolite of glucosamine, glucosamine
6-phosphate. Whole-cell patch clamp experiments in RBL-2 cells
determined that glucosamine 6-phosphate, but not other intracellular
metabolites of glucosamine, inhibited the trans-plasma membrane current
ICRAC, the Ca2+
release activated Ca2+
current regulated by Ca2+ store depletion and responsible
for capacitative Ca2+ entry in those cells. We propose that
this metabolite is also responsible for the inhibition seen here in
J774 cells.
Increased flux through the glucosamine pathway that could lead to the
accumulation of intracellular glucosamine metabolites has been reported
to be a response to hyperglycemia (49). In addition, such increases may
occur in response to dietary glucosamine, which is currently being
widely used as an alternative treatment for osteoarthritis (12). An
inhibition in capacitative Ca2+ entry due to excessive
hexosamine biosynthesis could affect a number of physiological
processes, including several important to the capacity to combat
infections and the onset of inflammation. For instance, increases in
[Ca2+]i have been shown to accompany phagocytosis
in macrophages (42) and to be necessary for phagosome/lysosome fusion
in neutrophils (50). However, phagosome/lysosome fusion in macrophages
appears to be a Ca2+-independent event (51).
In addition, capacitative Ca2+ entry is important to
certain aspects of gene regulation. The best described examples of this involve transcription mediated by members of the nuclear factor of
activated T cells family. These transcription factors require capacitative Ca2+ entry in order to provide for the ongoing
activation of calcineurin and the subsequent sustained nuclear
localization of nuclear factor of activated T cells family members
(40). This transcription factor family is critical to production of a
number of cytokines that greatly influence both the selection of
peripheral T cell populations and the function of other cells more
directly involved in combating infections. For instance,
granulocyte-macrophage colony-stimulating factor is dependent upon an
nuclear factor of activated T cells family member for its
transcriptional control (40). Such alterations in cytokine environment
could be expected to have effects on host defense against a variety of
infectious agents.
Because glucosamine metabolites increase during hyperglycemia (49), the
inhibition of capacitative Ca2+ entry seen here may be
relevant to the inability of diabetic individuals to effectively combat
infections. For instance, Rayfield et al. (52) found a
striking correlation between the prevalence of infection and mean
plasma glucose levels in diabetic outpatients. Consistent with these
data is a more recent report by Zerr et al. (48) in which
infection rates increased with blood glucose in patients recovering
from chest surgery. Those individuals with the highest blood glucose
levels suffered from rates of infection more than 15 times those seen
in a control population. Interestingly, implementation of a glucose
control protocol led to a 40% drop in infection rate among the
diabetic population.
Last, glucosamine is currently being widely used as an alternative
treatment for osteoarthritis (12). The data presented here suggest
that, rather than acting to enhance glycosaminoglycan synthesis, a
change in cytokine profiles and subsequent decreases in inflammatory
immune responses could underlie the putative effectiveness of such treatments.
 |
ACKNOWLEDGEMENTS |
We thank Sherry Crittenden for expert
secretarial assistance and Pam Bounelis, Ph.D. for her insightful
critique and assistance with graphics.
 |
FOOTNOTES |
*
This work was supported by the Fifty 50 Foods Diabetes
Interdisciplinary Research Program of the Juvenile Diabetes Foundation International and the American Diabetes Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell Biology,
Basic Health Sciences Bldg. 690, The University of Alabama at
Birmingham, University Station, Birmingham, AL 35294-0005. Tel.:
205-934-1294; Fax: 205-934-0950; E-mail: marchase@uab.edu.
2
P. Bounelis, Z. Su, E. A. Johnson, H. McFerrin, W. Bennett, J. E. Blalock, and R. B. Marchase,
submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
2dGlc, 2-deoxy-D-glucose;
HBS, Hepes-buffered saline solution;
GTP S, guanosine 5'-3-O-(thio)triphosphate;
Tg, thapsigargin;
stp, staurosporine.
 |
REFERENCES |
| 1.
|
Quastel, J. H.,
and Cantero, A.
(1953)
Nature
171,
252-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Friedman, S. J.,
and Skehan, P.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
1172-1176[Abstract/Free Full Text]
|
| 3.
|
Marshall, S.,
Bacote, V.,
and Traxinger, R. R.
(1991)
J. Biol. Chem.
266,
4706-4712[Abstract/Free Full Text]
|
| 4.
|
Rossetti, L.,
Hawkins, M.,
Chen, W.,
Gindi, J.,
and Barzilai, N.
(1995)
J. Clin. Invest.
96,
132-140
|
| 5.
|
Kim, Y.-B.,
Zhu, J.-S.,
Zierath, J. R.,
Shen, H.-Q.,
Baron, A. D.,
and Kahn, B. B.
(1999)
Diabetes
48,
310-320[Abstract]
|
| 6.
|
Crook, E. D.,
Daniels, M. C.,
Smith, T. M.,
and McClain, D. A.
(1993)
Diabetes
42,
1289-1296[Abstract]
|
| 7.
|
Hebert, L. F., Jr.,
Daniels, M. C.,
Zhou, J.,
Crook, E. D.,
Turner, R. L.,
Simmons, S. T.,
Neidigh, J. L.,
Zhu, J. S.,
Baron, A. D.,
and McClain, D. A.
(1996)
J. Clin. Invest.
98,
930-936[Medline]
[Order article via Infotrieve]
|
| 8.
|
Daniels, M. C.,
Kansal, P.,
Smith, T. M.,
Paterson, A. J.,
Kudlow, J. E.,
and McClain, D. A.
(1993)
Mol. Endocrinol.
7,
1041-1048[Abstract/Free Full Text]
|
| 9.
|
Kolm-Litty, V.,
Sauer, U.,
Nerlich, A.,
Lehmann, R.,
and Schleicher, E. D.
(1998)
J. Clin. Invest.
101,
160-169[Medline]
[Order article via Infotrieve]
|
| 10.
|
Wang, J.,
Liu, R.,
Hawkins, M.,
Barzilai, N.,
and Rossetti, L.
(1998)
Nature
393,
684-688[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Hresko, R. C.,
Heimberg, H.,
Chi, M. M.-Y.,
and Mueckler, M.
(1998)
J. Biol. Chem.
273,
20658-20668[Abstract/Free Full Text]
|
| 12.
|
Theodosakis, J.,
Adderly, B.,
and Fox, B.
(1997)
The Arthritis Cure
, St. Martin's Press, New York
|
| 13.
|
Qiu, G. X.,
Gao, S. N.,
Giacovelli, G.,
Rovati, L.,
and Setnikar, I.
(1998)
Arzneim. Forsch.
48,
469-474[Medline]
[Order article via Infotrieve]
|
| 14.
|
Barclay, T. S.,
Tsourounis, C.,
and McCart, G. M.
(1998)
Ann. Pharmacother.
32,
574-579[Abstract]
|
| 15.
|
Thastrup, O.,
Cullen, P. J.,
Drobak, B. K.,
Hanley, M. R.,
and Dawson, A. P.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2466-2470[Abstract/Free Full Text]
|
| 16.
|
Clapham, D. E.
(1995)
Cell
80,
259-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Putney, J. W., Jr.,
and Bird, G. S. J.
(1993)
Endocr. Rev.
14,
610-631[Abstract/Free Full Text]
|
| 18.
|
Petersen, C. C. H.,
and Berridge, M. J.
(1994)
J. Biol. Chem.
269,
32246-32253[Abstract/Free Full Text]
|
| 19.
|
Berridge, M. J.
(1995)
Biochem. J.
312,
1-11
|
| 20.
|
Jaconi, M.,
Pyle, J.,
Bortolon, R.,
Ou, J.,
and Clapham, D.
(1997)
Curr. Biol.
7,
599-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Randriamampita, C.,
and Tsien, R. Y.
(1993)
Nature
364,
809-818[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Parekh, A. B.,
Terlau, H.,
and Stuhmer, A.
(1993)
Nature
364,
814-818[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Kim, H. Y.,
Thomas, D.,
and Hanley, M. R.
(1995)
J. Biol. Chem.
270,
9706-9708[Abstract/Free Full Text]
|
| 24.
|
Thomas, D.,
Kim, H. Y.,
and Hanley, M. R.
(1996)
Biochem. J.
318,
649-656
|
| 25.
|
Csutora, P.,
Su, Z.,
Kim, H. Y.,
Bugrim, A.,
Cunningham, K. W.,
Nuccitelli, R.,
Keizer, J. E.,
Hanley, M. R.,
Blalock, J. E.,
and Marchase, R. B.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
121-126[Abstract/Free Full Text]
|
| 26.
|
Shibata, K.,
Morita, K.,
Kitayama, S.,
Okamoto, H.,
and Dohi, T.
(1996)
Biochem. Pharmacol.
52,
167-171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Morley, P.,
Chakravarthy, B. R.,
Mealing, G. A. R.,
Tsang, B. K.,
and Whitfield, J. F.
(1996)
Eur. J. Endocrinol.
134,
734-750
|
| 28.
|
Gamberucci, A.,
Innocenti, B.,
Fulceri, R.,
Banhegyi, G.,
Guinti, R.,
Pozzan, T.,
and Benedetti, A.
(1994)
J. Biol. Chem.
269,
23597-23602[Abstract/Free Full Text]
|
| 29.
|
Marriott, I.,
and Mason, M. J.
(1995)
Am. J. Physiol.
269,
C766-C774[Abstract/Free Full Text]
|
| 30.
|
Darbha, S.,
and Marchase, R. B.
(1996)
Cell Calcium
20,
361-371[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Randriamampita, C.,
and Tsien, R. Y.
(1995)
J. Biol. Chem.
270,
29-32[Abstract/Free Full Text]
|
| 32.
|
Thomas, D.,
and Hanley, M. R.
(1995)
J. Biol. Chem.
270,
6429-6432[Abstract/Free Full Text]
|
| 33.
|
Parekh, A. B.,
and Penner, R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7907-7911[Abstract/Free Full Text]
|
| 34.
|
Meggio, F.,
Donella Deana, A.,
Ruzzene, M.,
Brunati, A. M.,
Cesaro, L.,
Guerra, B.,
Meyer, T.,
Mett, H.,
Fabbro, D.,
Furet, P.,
Dobrawalska, G.,
and Pinna, L. A.
(1995)
Eur. J. Biochem.
234,
317-322[Medline]
[Order article via Infotrieve]
|
| 35.
|
Liu, X.,
O'Connell, A.,
and Ambudkar, I. S.
(1998)
J. Biol. Chem.
273,
33295-33304[Abstract/Free Full Text]
|
| 36.
|
Tojyo, Y.,
Tanimura, A.,
and Matsumoto, Y.
(1995)
Jpn. J. Pharmacol.
69,
381-389[Medline]
[Order article via Infotrieve]
|
| 37.
|
Petersen, C. C. H.,
and Berridge, M. J.
(1995)
Biochem. J.
307,
663-668
|
| 38.
|
Mene, P.,
Pugliese, F.,
and Cinotti, G. A.
(1996)
J. Am. Soc. Nephrol.
7,
983-990[Abstract]
|
| 39.
|
Ahnadi, C. E.,
Payet, M. D.,
and Dupuis, G.
(1996)
Cell Calcium
19,
509-520[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Rao, A.,
Luo, C.,
and Hogan, P. G.
(1997)
Annu. Rev. Immunol.
15,
707-747[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Dolmetsch, R. E.,
Lewis, R. S.,
Goodenow, C. C.,
and Healy, J. I.
(1997)
Nature
386,
855-858[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
DiVirgilio, F.,
Meyer, B. S.,
Greenberg, S.,
and Silverstein, S. C.
(1988)
J. Cell Biol.
106,
657-666[Abstract/Free Full Text]
|
| 43.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 44.
|
Tojyo, Y.,
Tanimura, A.,
Matsui, S.,
Matsumoto, Y.,
Sugiya, H.,
and Furuyama, S.
(1991)
Am. J. Physiol.
260,
C194-C200[Abstract/Free Full Text]
|
| 45.
|
Merritt, J. E.,
Armstrong, W. P.,
Benham, C. D.,
Hallam, T. J.,
Jacob, R.,
Jaxa-Chamiec, A.,
Leigh, B. K.,
and McCarthy, S. A.
(1990)
Biochem. J.
271,
515-522[Medline]
[Order article via Infotrieve]
|
| 46.
|
Salter, D. W.,
and Weber, M. J.
(1979)
J. Biol. Chem.
254,
3554-3561[Free Full Text]
|
| 47.
|
Atlas, S. J.,
Magargal, W. W.,
and Lin, S.
(1980)
J. Recept. Res.
1,
113-135[Medline]
[Order article via Infotrieve]
|
| 48.
|
Zerr, K. J.,
Furnary, A. P.,
Grunkemeier, G. L.,
Bookin, S.,
Kanhere, V.,
and Starr, A.
(1997)
Ann. Thorac. Surg.
63,
356-361[Abstract/Free Full Text]
|
| 49.
|
Buse, M. G.,
Robinson, K. A.,
Gettys, T. W.,
McMahon, E. G.,
and Gulve, E. A.
(1997)
Am. J. Physiol.
272,
E1080-E1088[Abstract/Free Full Text]
|
| 50.
|
Jaconi, M. E.,
Lew, D. P.,
Carpentier, J. L.,
Magnusson, K. E.,
Sjogren, M.,
and Stendahl, O.
(1990)
J. Cell Biol.
110,
1555-1564[Abstract/Free Full Text]
|
| 51.
|
Zimmerli, S.,
Majeed, M.,
Gustavsson, M.,
Stendahl, O.,
Sanan, D. A.,
and Ernst, J. D.
(1996)
J. Cell Biol.
132,
49-61[Abstract/Free Full Text]
|
| 52.
|
Rayfield, E. J.,
Ault, M. J.,
Keusch, G. T.,
Brothers, M. J.,
Nechemias, C.,
and Smith, H.
(1982)
Am. J. Med.
72,
439-450[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Nagy, V. Champattanachai, R. B. Marchase, and J. C. Chatham
Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine
Am J Physiol Cell Physiol,
January 1, 2006;
290(1):
C57 - C65.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E. Zachara, N. O'Donnell, W. D. Cheung, J. J. Mercer, J. D. Marth, and G. W. Hart
Dynamic O-GlcNAc Modification of Nucleocytoplasmic Proteins in Response to Stress: A SURVIVAL RESPONSE OF MAMMALIAN CELLS
J. Biol. Chem.,
July 16, 2004;
279(29):
30133 - 30142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Hunton, L. Zou, Y. Pang, and R. B. Marchase
Adult rat cardiomyocytes exhibit capacitative calcium entry
Am J Physiol Heart Circ Physiol,
March 1, 2004;
286(3):
H1124 - H1132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Pang, D. L. Hunton, P. Bounelis, and R. B. Marchase
Hyperglycemia Inhibits Capacitative Calcium Entry and Hypertrophy in Neonatal Cardiomyocytes
Diabetes,
December 1, 2002;
51(12):
3461 - 3467.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|